Journal
NEUROBIOLOGY OF AGING
Volume 34, Issue 2, Pages 374-386Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2012.05.003
Keywords
Calcineurin; Tau; Alzheimer's disease; Phosphorylation
Categories
Funding
- AstraZeneca
- National Institutes of Health [P01AG003991, P50AG005681]
Ask authors/readers for more resources
Alzheimer's disease (AD) is characterized by neuronal loss and the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain. Cerebrospinal fluid (CSF) levels of beta-amyloid and tau/phospho-tau181 (ptau181) are also associated with AD. We have previously demonstrated that a single nucleotide polymorphism in calcineurin is associated with CSF ptau181 levels and AD progression. In this study, we demonstrate that calcineurin protein levels are inversely correlated with dementia severity and Braak tangle stage in AD brains, and calcineurin activity is globally reduced in AD brains. We then sought to model the observed changes in CSF tau by measuring extracellular tau in cultured cells. SH-SY5Y cells treated with calcineurin inhibitors produced reduced calcineurin activity and a corresponding increase in extracellular ptau181. These findings are consistent with our observations in AD patients, who have elevated CSF ptau181 and reduced calcineurin activity in brain extracts. Thus, we have identified a gene that contributes to AD pathology and has functional consequences on tau metabolism in cultured cells. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available